Cargando…
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
LESSONS LEARNED. Trebananib leveraging anti‐angiogenic mechanism that is distinct from the classic sorafenib anti‐vascular endothelial growth factor inhibition did not demonstrate improved progression‐free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC). In support of p...
Autores principales: | Abou‐Alfa, Ghassan K., Blanc, Jean‐Frederic, Miles, Steven, Ganten, Tom, Trojan, Jörg, Cebon, Jonathan, Liem, Andre K., Lipton, Lara, Gupta, Charu, Wu, Benjamin, Bass, Michael, Hollywood, Ellen, Ma, Jennifer, Bradley, Margaret, Litten, Jason, Saltz, Leonard B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507650/ https://www.ncbi.nlm.nih.gov/pubmed/28592620 http://dx.doi.org/10.1634/theoncologist.2017-0058 |
Ejemplares similares
-
A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018) -
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016) -
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
por: El Dika, Imane, et al.
Publicado: (2018) -
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
por: Uldrick, Thomas S., et al.
Publicado: (2017) -
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)